ClinicalTrials.gg
TerminatedNCT00334685Updated Dec 16, 2019

[S,S]-Reboxetine Add-On Trial

A Phase 2 interventional study of [S,S]-Reboxetine + Pregabalin and Pregabalin in Pain, sponsored by Pfizer. Terminated at 83 sites in 16 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-12-16.

Sponsored by Pfizer · Phase 2, Interventional, and Treatment

Why this study was terminated
The Data Monitoring Committee terminated the study on the basis of futility (insufficient clinical response).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
136
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 55 studies testing pregabalin in Pain — 4 open to participants now, 4 under way, none of them phase 3. Pregabalin · Pain.

Enrollment
19th of 55
136 · median 64
Started
2006
with 2 others
Phase 2
7 of 55
none open now
Registered
3rd of 55
by date
Lead sponsor
2 of 55
Pfizer

Among the 55 studies testing pregabalin in Pain, this one is the 19th largest by enrollment, is one of 3 that started in 2006, is one of 7 in phase 2, and was the 3rd registered.

Pain

10,075 studies on the registry are indexed under Pain; 1,649 are open to participants now.

Browse Pain studies →

Open to participants now

4 of the 55 studies testing pregabalin in Pain are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About pregabalin

Pregabalin: first FDA approval 2004 (LYRICA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 929 Pain studies recruiting now, 384 (41%) set no upper age limit and 433 (47%) stop at 75 or younger; 145 take children under 18; 220 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 55 studies testing pregabalin in Pain, or all of them as a file.
02

Study summary

The purpose of this study is to determine the effectiveness of adjunctive treatment of pregabalin with [S,S]-Reboxetine against pregabalin monotherapy in patients with PHN

03

Conditions studied

  • Pain

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients must have pain present for more than 3 months after the healing of shingles skin rash
  • Patients at screening must have a score >/=40 mm on the pain visual analogue scale

Exclusion criteria

Exclusion Criteria:

  • Patients with significant renal and hepatic impairment
  • Patients with other severe pain, that may impair the self-assessment of the pain due to shingles
  • Patients with clinically abnormal
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
136 participants (actual)

Study arms

  • Experimental
    [S,S]-Reboxetine + Pregabalin

    Drug: [S,S]-Reboxetine + Pregabalin

  • Active comparator
    Pregabalin

    Drug: Pregabalin

Interventions

  • Drug[S,S]-Reboxetine + Pregabalin

    Drug pages: Reboxetine · Pregabalin

    \[S,S\]-Reboxetine oral, tablet 2, 4 or 6 mg per day for 10 weeks Pregabalin oral, capsule, 75, 150, 300 or 600 mg per day for 14 weeks

  • Pregabalin oral, capsule, 75, 150, 300 or 600 mg per day for 14 weeks

06

What researchers measure

Primary outcomes

  1. The numerical pain intensity rating scale is used to assess pain and a change from baseline in pain score for week 10 will be calculated

    Time frame: Week 10

Secondary outcomes

  1. The mean endpoint (week 10) sleep interference score change from baseline

    Time frame: Week 10

  2. Analysis of the Medical Outcomes Study Sleep Scale

    Time frame: Week 10

  3. Analysis of the Patient Global Impression of Change

    Time frame: Week 10

  4. Analysis of the Neuropathic Pain Symptom Inventory

    Time frame: Week 10

07

Study locations

83 sites
  • Pfizer Investigational Site
    Huntsville, Alabama 35801, United States
  • Pfizer Investigational Site
    Gilbert, Arizona 85234, United States
  • Pfizer Investigational Site
    North Dartmouth, Massachusetts 02747, United States
  • Pfizer Investigational Site
    Saint Louis, Missouri 63141, United States
  • Pfizer Investigational Site
    Amherst, New York 14226, United States
  • Pfizer Investigational Site
    Orchard Park, New York 14127, United States
  • Pfizer Investigational Site
    Kettering, Ohio 45429, United States
  • Pfizer Investigational Site
    Wien, A - 1090, Austria
  • Pfizer Investigational Site
    Calgary, Alberta T3C 3P1, Canada
  • Pfizer Investigational Site
    Calgary, Alberta T3E 0C5, Canada
  • Pfizer Investigational Site
    Edmonton, Alberta T5A 4L8, Canada
  • Pfizer Investigational Site
    Kelowna, British Columbia V1Y 2H4, Canada
  • Pfizer Investigational Site
    Langley, British Columbia V3A 4H9, Canada
  • Pfizer Investigational Site
    Hawkesbury, Ontario K6A 1A1, Canada
  • Pfizer Investigational Site
    North Bay, Ontario P1B 2H3, Canada
  • Pfizer Investigational Site
    Sudbury, Ontario K3E 3L6, Canada
  • Pfizer Investigational Site
    Sudbury, Ontario P3E 1H5, Canada
  • Pfizer Investigational Site
    Val Caron, Ontario P3N 1G3, Canada
  • Pfizer Investigational Site
    Pointe-Claire, Quebec H9R 4S3, Canada
  • Pfizer Investigational Site
    St-Romuald, Quebec G6W 5M6, Canada
  • Pfizer Investigational Site
    Regina, Saskatchewan S4P 3X1, Canada
  • Pfizer Investigational Site
    Saskatoon, Saskatchewan S7K 7H9, Canada
  • Pfizer Investigational Site
    Sasktatoon, Saskatchewan S7K 6Y6, Canada
  • Pfizer Investigational Site
    Quebec, G1V 4X7, Canada
  • Pfizer Investigational Site
    Ceske Budejovice, 370 87, Czechia
  • Pfizer Investigational Site
    Plzen, 304 60, Czechia
  • Pfizer Investigational Site
    Erbach, 64711, Germany
  • Pfizer Investigational Site
    Hattingen, 45525, Germany
  • Pfizer Investigational Site
    Jena, 07743, Germany
  • Pfizer Investigational Site
    Karlsruhe, 76199, Germany
  • Pfizer Investigational Site
    Katzhuette, 98746, Germany
  • Pfizer Investigational Site
    Mainz, 55101, Germany
  • Pfizer Investigational Site
    Mainz, 55116, Germany
  • Pfizer Investigational Site
    Muenchen, 81675, Germany
  • Pfizer Investigational Site
    Muenster, 48129, Germany
  • Pfizer Investigational Site
    Wiesbaden, 65189, Germany
  • Pfizer Investigational Site
    Milano, 20127, Italy
  • Pfizer Investigational Site
    Napoli, 80138, Italy
  • Pfizer Investigational Site
    Perugia, 06123, Italy
  • Pfizer Investigational Site
    Riga, LV 1002, Latvia
  • Pfizer Investigational Site
    Breda, 4819 EV, Netherlands
  • Pfizer Investigational Site
    Utrecht, 3584 CX, Netherlands
  • Pfizer Investigational Site
    Bekkestua, 1319, Norway
  • Pfizer Investigational Site
    Lierskogen, N-3421, Norway
  • Pfizer Investigational Site
    Oslo, 0027, Norway
  • Pfizer Investigational Site
    Sandnes, 4313, Norway
  • Pfizer Investigational Site
    Trondheim, 7031, Norway
  • Pfizer Investigational Site
    Krakow, 31-531, Poland
  • Pfizer Investigational Site
    Poznan, 61-289, Poland
  • Pfizer Investigational Site
    St. Petersburg, 194044, Russian Federation
  • Pfizer Investigational Site
    Yaroslavl, 150030, Russian Federation
  • Pfizer Investigational Site
    L'hospitalet de Llobregat, Barcelona 08907, Spain
  • Pfizer Investigational Site
    Cadiz, 11009, Spain
  • Pfizer Investigational Site
    Granada, 18014, Spain
  • Pfizer Investigational Site
    Madrid, 28006, Spain
  • Pfizer Investigational Site
    Sevilla, 41013, Spain
  • Pfizer Investigational Site
    Valencia, 46014, Spain
  • Pfizer Investigational Site
    Eksjo, 575 81, Sweden
  • Pfizer Investigational Site
    Goteborg, 413 45, Sweden
  • Pfizer Investigational Site
    Goteborg, 416 85, Sweden
  • Pfizer Investigational Site
    Karlstad, 651 85, Sweden
  • Pfizer Investigational Site
    Skelleftea, 931 86, Sweden
  • Pfizer Investigational Site
    Stockholm, 114 54, Sweden
  • Pfizer Investigational Site
    Zurich, 8008, Switzerland
  • Pfizer Investigational Site
    Dnipropetrovsk, 49616, Ukraine
  • Pfizer Investigational Site
    Donetsk, 83045, Ukraine
  • Pfizer Investigational Site
    Kharkiv, 310057, Ukraine
  • Pfizer Investigational Site
    Kharkiv, 61018, Ukraine
  • Pfizer Investigational Site
    Kharkiv, 61068, Ukraine
  • Pfizer Investigational Site
    Kharkiv, 61178, Ukraine
  • Pfizer Investigational Site
    Kyiv, 01021, Ukraine
  • Pfizer Investigational Site
    Kyiv, 04112, Ukraine
  • Pfizer Investigational Site
    Odessa, 65025, Ukraine
  • Pfizer Investigational Site
    Simferopol, 95006, Ukraine
  • Pfizer Investigational Site
    Uzhgorod, 88011, Ukraine
  • Pfizer Investigational Site
    Portsmouth, Hampshire PO3 6AD, United Kingdom
  • Pfizer Investigational Site
    London, UK SE13 6LH, United Kingdom
  • Pfizer Investigational Site
    Birmingham, West Midlands B29 6JD, United Kingdom
  • Pfizer Investigational Site
    Glasgow, G42 9YU, United Kingdom
  • Pfizer Investigational Site
    London, EC1A 7BE, United Kingdom
  • Pfizer Investigational Site
    Manchester, M8 5RB, United Kingdom
  • Pfizer Investigational Site
    Plymouth, PL6 8DH, United Kingdom
  • Pfizer Investigational Site
    York, YO31 8HE, United Kingdom
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2006 to primary completion in Oct 2007, 13 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 7, 2006
First posted
Jun 8, 2006
StartActual
Aug 22, 2006
Primary completionActual
Oct 4, 2007
CompletionActual
Oct 11, 2007
Last update
Dec 16, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 16, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00334685
Lead sponsor
Pfizer
First posted
Jun 8, 2006
Start date
Aug 22, 2006
Primary completion
Oct 4, 2007
Completion
Oct 11, 2007
Last update
Dec 16, 2019

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Dec 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Reboxetine · Pregabalin

Start the discussion